Candesartan

Blopress, Blopresid e altri

Bibliografia - Quali fonti bibliografiche per Candesartan?

1. Agenzia Italiana del Farmaco – AIFA, Blopress - Riassunto Caratteristiche di Prodotto, 2013.


2. Agenzia Italiana del Farmaco – AIFA, Candesartan Zentiva - Riassunto Caratteristiche di Prodotto, 2015.


3. Agenzia Italiana del Farmaco – AIFA, Candesartan e Idroclorotiazide Mylan - Riassunto Caratteristiche di Prodotto, 2015a.


4. Alldredge B. et al., Koda-Kimble and young’s applied therapeutics: the clinical use of drugs, 2012, Lippincott Williams & Wilkins.


5. Alwan S. et al., Birth Defects Res. A. Clin. Mol. Teratol., 2005, 73 (2), 123.


6. Barreras A., Gurk-Turner C., Proc. (Bayl. Univ. Med. Cent.), 2003, 16 (1), 123.


7. Brabant S.M. et al., Anesth. Analg., 1999, 89 (6), 1388.


8. Darby M. et al., Expert. Opin. Drug Saf., 2013, 12 (6), 857.


9. De Zeeuw D. et al., J. Hum. Hypertens., 1997, 11 Suppl. 2, S37.


10. EL Feghali R. et al., Vasc. Health Risk Manag., 2007, 3 (1), 165.


11. El Feghali R. et al., Arch. Mal. Coeur Vaiss., 2007a, 100 (8), 679.


12. European Medicines Agency – EMA, Press release, 2012, 17 febbraio.


13. Finley P.R. et al., J. Clin. Psychopharmacol., 1996, 16 (1), 68.


14. Food and Drug Administration – FDA, Atacand Label Information, 2015.


15. Fridman K. et al., Am. J. Hypertens., 2000, 13 (9), 1045.


16. Gleiter C.H., Morike KE., Clin. Pharmacokinet., 2002, 41 (1), 7.


17. Heeg J.E. et al., Am. J. Nephrol., 1990, 10 Suppl. 1, 94.


18. Hubner R. et al., J. Hum. Hypertens., 1997, 11 Suppl. 2, S19.


19. Husain A. et al., Journal of Applied Pharmaceutical Science, 2011, 01 (10), 12.


20. Israili Z.H., J. Hum. Hypertens., 2000, 14 Suppl. 1, S73.


21. Kamel R. et al., Immunopharmacol. Immunotoxicol., 2012, 34 (6), 956.


22. Katsung G., Farmacologia generale e clinica, 2014, Piccin.


23. Lansang M.C. et al., Hypertension., 2000, 36 (5), 834.


24. Maddirala S. et al., Am. J. Med. Sci., 2008, 336 (4), 330.


25. McMurray J. et al., Eur. J. Heart Fail., 2003, 5 (3), 261.


26. Meredith P.A., Curr. Med. Res. Opin., 2007, 23 (7), 1693.


27. Mosby, Mosby’s drug reference for health professions, 2015, Elsevier Health Sciences.


28. Mozayani A., Raymon L., Handbook of drug interactions: A clinical and forensic guide, 2011, Springer Science & Business Media.


29. Nakamura T. et al., J. Stroke Cerebrovasc. Dis., 2010, 19 (6), 435.


30. Nishimura Y. et al., Stroke, 2000, 31 (10), 2478.


31. Perico N. et al., J. Am. Soc. Nephrol., 1998, 9 (12), 2308.


32. Pfeffer M.A. et al., Lancet, 2003, 362 (9386), 759.


33. Raebel M.A., Cardiovasc. Ther., 2012, 30 (3), e156.


34. Ray J. et al., Can. Fam. Physician, 2007, 53 (9), 1439.


35. Ripley T. et al., Clin. Interv. Aging, 2006, 1 (4), 357.


36. Schoolwerth A.C. et al., Circulation, 2001, 104 (16), 1985.


37. Schwartz G. et al., Am. J. Hypertens., 2013, 26 (8), 957.


38. See S., Stirling AL., Am. J. Health Syst. Pharmacol., 2000, 57 (8), 739.


39. Shibata S. et al., Masui, 2005, 54 (6), 670.


40. Tanser P.H. et al., Am. J. Hypertens., 2000, 13 (2), 214.


41. Trenkwalder P., Basic Res. Cardiol., 1998, 93 Suppl. 2, 140.


42. Vaguero Roncero L.M. et al., Rev. Esp. Anestesiol. Reanim., 2004, 51 (6), 338.